Intervention Review

You have free access to this content

Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals

  1. Lawrence CE Mbuagbaw1,*,
  2. James H Irlam2,
  3. Alicen Spaulding3,
  4. George W Rutherford4,
  5. Nandi Siegfried5

Editorial Group: Cochrane HIV/AIDS Group

Published Online: 8 DEC 2010

Assessed as up-to-date: 8 FEB 2009

DOI: 10.1002/14651858.CD004246.pub3


How to Cite

Mbuagbaw LCE, Irlam JH, Spaulding A, Rutherford GW, Siegfried N. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Cochrane Database of Systematic Reviews 2010, Issue 12. Art. No.: CD004246. DOI: 10.1002/14651858.CD004246.pub3.

Author Information

  1. 1

    Centre for the Development of Best Practices in Health, Yaoundé, Cameroon

  2. 2

    University of Cape Town, Primary Health Care Directorate, Cape Town, Western Cape, South Africa

  3. 3

    University of Minnesota, Division of Epidemiology and Community Health, Minneapolis, Minnesota, USA

  4. 4

    University of California, San Francisco, Global Health Sciences, San Francisco, California, USA

  5. 5

    University of Cape Town, Department of Public Health and Primary Health Care, Cape Town, South Africa

*Lawrence CE Mbuagbaw, Centre for the Development of Best Practices in Health, Henri Dunant Avenue, PO Box 87, Yaoundé, Cameroon. mbuagbawl@yahoo.com.

Publication History

  1. Publication Status: Stable (no update expected for reasons given in 'What's new')
  2. Published Online: 8 DEC 2010

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Gary Maartens, ART and tuberculosis: the final nail in nevirapine's coffin?, The Lancet Infectious Diseases, 2013, 13, 4, 278

    CrossRef

  2. 2
    Maryline Bonnet, Nilesh Bhatt, Elisabeth Baudin, Carlota Silva, Christophe Michon, Anne-Marie Taburet, Laura Ciaffi, Agnès Sobry, Rui Bastos, Elizabete Nunes, Christine Rouzioux, Ilesh Jani, Alexandra Calmy, Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial, The Lancet Infectious Diseases, 2013, 13, 4, 303

    CrossRef

  3. 3
    Jean-Michel Molina, Pedro Cahn, Beatriz Grinsztejn, Adriano Lazzarin, Anthony Mills, Michael Saag, Khuanchai Supparatpinyo, Sharon Walmsley, Herta Crauwels, Laurence T Rimsky, Simon Vanveggel, Katia Boven, Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial, The Lancet, 2011, 378, 9787, 238

    CrossRef

  4. 4
    Calvin J Cohen, Jaime Andrade-Villanueva, Bonaventura Clotet, Jan Fourie, Margaret A Johnson, Kiat Ruxrungtham, Hao Wu, Carmen Zorrilla, Herta Crauwels, Laurence T Rimsky, Simon Vanveggel, Katia Boven, Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial, The Lancet, 2011, 378, 9787, 229

    CrossRef